专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20060292623A1 Signature genes in chronic myelogenous leukemia 审中-公开
公开(公告)号：US20060292623A1
公开(公告)日：2006-12-28
申请号：US11510798
申请日：2006-08-25
申请人： Peter Linsley , Mao Mao , Hongyue Dai , Yudong He , Jerald Radich
发明人： Peter Linsley , Mao Mao , Hongyue Dai , Yudong He , Jerald Radich
IPC分类号： C12Q1/68 , G06F19/00
CPC分类号： G01N33/57426 , C12Q1/6837 , C12Q1/6886 , C12Q2600/158 , G16B25/00
摘要： The present invention relates to genetic markers whose expression is correlated with progression of CML. Specifically, the invention provides sets of markers whose expression patterns can be used to differentiate chronic phase individuals from those in blast crisis. The invention relates to methods of using these markers to distinguish these conditions. The invention also relates to kits containing ready-to-use microarrays and computer software for data analysis using the statistical methods disclosed herein.

2. 发明申请

US20070154931A1 Genes associate with progression and response in chronic myeloid leukemia and uses thereof 失效
标题翻译：与慢性骨髓性白血病中进展和反应相关的基因及其用途
公开(公告)号：US20070154931A1
公开(公告)日：2007-07-05
申请号：US11640517
申请日：2006-12-14
申请人： Jerald Radich , Hongyue Dai , Mao Mao , Janell Schelter , Peter Linsley
发明人： Jerald Radich , Hongyue Dai , Mao Mao , Janell Schelter , Peter Linsley
IPC分类号： C12Q1/68 , G06F19/00
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/112 , C12Q2600/136 , C12Q2600/158 , Y02A90/26
摘要： The invention provides molecular markers that are associated with the progression of chronic myeloid leukemia (CML), and methods and computer systems for monitoring the progression of CML in a patient based on measurements of these molecular markers. The present invention also provides CML target genes, and methods and compositions for treating CML patients by modulating the expression or activity of these CML target genes and/or their encoded proteins. The invention also provides genes that are associated with resistance to imatinib mesylate (Gleevec™) treatment in CML patients, and methods and compositions for determining the responsiveness of a CML patient to imatinib mesylate treatment based on measurements of these genes and/or their encoded proteins. The invention also provides methods and compositions for enhancing the effect of Gleevec™ by modulating the expression or activity of these genes and/or their encoded proteins.
摘要翻译：本发明提供了与慢性骨髓性白血病（CML）进展相关的分子标记，以及用于基于这些分子标记物的测量来监测患者中CML进展的方法和计算机系统。本发明还提供CML靶基因，以及通过调节这些CML靶基因和/或其编码蛋白的表达或活性来治疗CML患者的方法和组合物。本发明还提供了与CML患者中对甲磺酸伊马替尼（Gleevec TM）的抗药性相关的基因，以及基于这些基因和/或它们的测量来确定CML患者对甲磺酸伊马替尼治疗的反应性的方法和组合物编码的蛋白质。本发明还提供了通过调节这些基因和/或其编码的蛋白质的表达或活性来增强Gleevec TM的作用的方法和组合物。

3. 发明申请

US20090157326A1 Diagnosis and prognosis of breast cancer patients 有权
标题翻译：乳腺癌患者的诊断和预后
公开(公告)号：US20090157326A1
公开(公告)日：2009-06-18
申请号：US12214878
申请日：2008-06-23
申请人： HongYue Dai , Yudong He , Peter S. Linsley , Mao Mao , Christopher J. Roberts , Laura Johanna Van't Veer , Marc J. Van de Vijver , Rene Bernards , Augustinus A.M. Hart
发明人： HongYue Dai , Yudong He , Peter S. Linsley , Mao Mao , Christopher J. Roberts , Laura Johanna Van't Veer , Marc J. Van de Vijver , Rene Bernards , Augustinus A.M. Hart
IPC分类号： G06F19/00
CPC分类号： C12Q1/6886 , C12Q2600/158 , G01N33/57415 , G06F19/00 , G06F19/20 , G06F19/24 , Y02A90/22 , Y02A90/26
摘要： The present invention relates to genetic markers whose expression is correlated with breast cancer. Specifically, the invention provides sets of markers whose expression patterns can be used to differentiate clinical conditions associated with breast cancer, such as the presence or absence of the estrogen receptor ESR1, and BRCA1 and sporadic tumors, and to provide information on the likelihood of tumor distant metastases within five years of initial diagnosis. The invention relates to methods of using these markers to distinguish these conditions. The invention also relates to kits containing ready-to-use microarrays and computer software for data analysis using the statistical methods disclosed herein.
摘要翻译：本发明涉及其表达与乳腺癌相关的遗传标记。具体地，本发明提供了一组标志物，其表达模式可用于区分与乳腺癌相关的临床病症，例如雌激素受体ESR1和BRCA1和散发性肿瘤的存在或不存在，并提供关于肿瘤可能性的信息初步诊断五年内远处转移。本发明涉及使用这些标记来区分这些条件的方法。本发明还涉及包含即用型微阵列的试剂盒和用于使用本文公开的统计学方法进行数据分析的计算机软件。

4. 发明申请

US20090239214A1 Prognosis of breast cancer patients 审中-公开
标题翻译：乳腺癌患者预后
公开(公告)号：US20090239214A1
公开(公告)日：2009-09-24
申请号：US11658605
申请日：2005-08-01
申请人： Hongyue Dai , Yudong He , Mao Mao , Bernard Fine , Laura J. van't Veer , Marc J. van de Vijver
发明人： Hongyue Dai , Yudong He , Mao Mao , Bernard Fine , Laura J. van't Veer , Marc J. van de Vijver
IPC分类号： C12Q1/68 , G06F19/00
CPC分类号： G01N33/57415 , B01J2219/00378 , B01J2219/00385 , B01J2219/00527 , B01J2219/00576 , B01J2219/00585 , B01J2219/00596 , B01J2219/00605 , B01J2219/0061 , B01J2219/00612 , B01J2219/00626 , B01J2219/00641 , B01J2219/00675 , B01J2219/00677 , B01J2219/00693 , B01J2219/00711 , B01J2219/00722 , B82Y30/00 , C12Q1/6886 , C12Q2600/106 , C12Q2600/112 , C12Q2600/118 , G16B25/00 , G16B40/00
摘要： The present invention relates to sets of genetic markers whose expression is correlated with prognosis of breast cancer in individuals having breast cancer. Specifically, the invention provides sets of markers whose expression patterns can be used to differentiate individuals having a good prognosis, e.g., no reoccurrence or metastasis within five years of initial diagnosis, and individuals having a poor prognosis, e.g., reoccurrence or metastasis within five years of initial diagnosis. The invention relates to methods of prognosis using these markers. The invention also relates to microarrays containing probes to these markers, and to kits containing ready-to-use microarrays and computer software for data analysis using the prognostic and statistical methods disclosed herein.
摘要翻译：本发明涉及具有乳腺癌个体的表达与乳腺癌预后相关的遗传标记组。具体地，本发明提供了一组标志物，其表达模式可用于区分具有良好预后的个体，例如在初始诊断的五年内不再发生或转移，以及在五年内具有差的预后，例如再发生或转移的个体的初步诊断。本发明涉及使用这些标记物的预后方法。本发明还涉及含有这些标记物的探针的微阵列，以及包含即用型微阵列的试剂盒和用于使用本文公开的预后和统计学方法进行数据分析的计算机软件。

5. 发明授权

US07863001B2 Diagnosis and prognosis of breast cancer patients 有权
标题翻译：乳腺癌患者的诊断和预后
公开(公告)号：US07863001B2
公开(公告)日：2011-01-04
申请号：US12214878
申请日：2008-06-23
申请人： HongYue Dai , Yudong He , Peter S. Linsley , Mao Mao , Christopher J. Roberts , Laura Johanna Van't Veer , Marc J. Van de Vijver , Rene Bernards , Augustinus A. M. Hart
发明人： HongYue Dai , Yudong He , Peter S. Linsley , Mao Mao , Christopher J. Roberts , Laura Johanna Van't Veer , Marc J. Van de Vijver , Rene Bernards , Augustinus A. M. Hart
IPC分类号： C12Q1/68 , G01N33/48 , C07H21/00
CPC分类号： C12Q1/6886 , C12Q2600/158 , G01N33/57415 , G06F19/00 , G06F19/20 , G06F19/24 , Y02A90/22 , Y02A90/26
摘要： The present invention relates to genetic markers whose expression is correlated with breast cancer. Specifically, the invention provides sets of markers whose expression patterns can be used to differentiate clinical conditions associated with breast cancer, such as the presence or absence of the estrogen receptor ESR1, and BRCA1 and sporadic tumors, and to provide information on the likelihood of tumor distant metastases within five years of initial diagnosis. The invention relates to methods of using these markers to distinguish these conditions. The invention also relates to kits containing ready-to-use microarrays and computer software for data analysis using the statistical methods disclosed herein.
摘要翻译：本发明涉及其表达与乳腺癌相关的遗传标记。具体地，本发明提供了一组标志物，其表达模式可用于区分与乳腺癌相关的临床病症，例如雌激素受体ESR1和BRCA1和散发性肿瘤的存在或不存在，并提供关于肿瘤可能性的信息初步诊断五年内远处转移。本发明涉及使用这些标记来区分这些条件的方法。本发明还涉及包含即用型微阵列的试剂盒和用于使用本文公开的统计学方法进行数据分析的计算机软件。

6. 发明授权

US07514209B2 Diagnosis and prognosis of breast cancer patients 有权
公开(公告)号：US07514209B2
公开(公告)日：2009-04-07
申请号：US10172118
申请日：2002-06-14
申请人： HongYue Dai , Yudong He , Peter S. Linsley , Mao Mao , Christopher J. Roberts , Laura Johanna Van't Veer , Marc J. Van de Vijver , Rene Bernards , Augustinus A. M. Hart
发明人： HongYue Dai , Yudong He , Peter S. Linsley , Mao Mao , Christopher J. Roberts , Laura Johanna Van't Veer , Marc J. Van de Vijver , Rene Bernards , Augustinus A. M. Hart
IPC分类号： C12Q1/68 , G01N33/48 , C07H21/00
CPC分类号： C12Q1/6886 , C12Q2600/158 , G01N33/57415 , G06F19/00 , G06F19/20 , G06F19/24 , Y02A90/22 , Y02A90/26
摘要： The present invention relates to genetic markers whose expression is correlated with breast cancer. Specifically, the invention provides sets of markers whose expression patterns can be used to differentiate clinical conditions associated with breast cancer, such as the presence or absence of the estrogen receptor ESR1, and BRCA1 and sporadic tumors, and to provide information on the likelihood of tumor distant metastases within five years of initial diagnosis. The invention relates to methods of using these markers to distinguish these conditions. The invention also relates to kits containing ready-to-use microarrays and computer software for data analysis using the statistical methods disclosed herein.

7. 发明申请

US20110301048A1 DIAGNOSIS AND PROGNOSIS OF BREAST CANCER PATIENTS 审中-公开
标题翻译：乳腺癌患者的诊断和预防
公开(公告)号：US20110301048A1
公开(公告)日：2011-12-08
申请号：US12953314
申请日：2010-11-23
申请人： HongYue Dai , Yudong He , Peter S. Linsley , Mao Mao , Christopher J. Roberts , Laura Johanna Van't Veer , Marc J. Van de Vijver , Rene Bernards , A.A. M. Hart
发明人： HongYue Dai , Yudong He , Peter S. Linsley , Mao Mao , Christopher J. Roberts , Laura Johanna Van't Veer , Marc J. Van de Vijver , Rene Bernards , A.A. M. Hart
IPC分类号： C40B30/02 , C40B40/06 , C40B30/04
CPC分类号： C12Q1/6886 , C12Q2600/158 , G01N33/57415 , G06F19/00 , G16B25/00 , G16B40/00 , Y02A90/22 , Y02A90/26
摘要： The present invention relates to genetic markers whose expression is correlated with breast cancer. Specifically, the invention provides sets of markers whose expression patterns can be used to differentiate clinical conditions associated with breast cancer, such as the presence or absence of the estrogen receptor ESR1, and BRCA1 and sporadic tumors, and to provide information on the likelihood of tumor distant metastases within five years of initial diagnosis. The invention relates to methods of using these markers to distinguish these conditions. The invention also relates to kits containing ready-to-use microarrays and computer software for data analysis using the statistical methods disclosed herein.
摘要翻译：本发明涉及其表达与乳腺癌相关的遗传标记。具体地，本发明提供了一组标志物，其表达模式可用于区分与乳腺癌相关的临床病症，例如雌激素受体ESR1和BRCA1和散发性肿瘤的存在或不存在，并提供关于肿瘤可能性的信息初步诊断五年内远处转移。本发明涉及使用这些标记来区分这些条件的方法。本发明还涉及包含即用型微阵列的试剂盒和用于使用本文公开的统计学方法进行数据分析的计算机软件。

8. 发明授权

US07171311B2 Methods of assigning treatment to breast cancer patients 有权
标题翻译：为乳腺癌患者分配治疗方法
公开(公告)号：US07171311B2
公开(公告)日：2007-01-30
申请号：US10342887
申请日：2003-01-15
申请人： Hongyue Dai , Yudong He , Peter S. Linsley , Mao Mao , Christopher J. Roberts , Laura Johanna Van't Veer , Marc J. Van de Vijver , Rene Bernards , A. A. M. Hart
发明人： Hongyue Dai , Yudong He , Peter S. Linsley , Mao Mao , Christopher J. Roberts , Laura Johanna Van't Veer , Marc J. Van de Vijver , Rene Bernards , A. A. M. Hart
IPC分类号： G01N33/48 , C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/112 , C12Q2600/118 , C12Q2600/136 , C12Q2600/158
摘要： The present invention relates to genetic markers whose expression is correlated with breast cancer. Specifically, the invention provides sets of markers whose expression patterns can be used to differentiate clinical conditions associated with breast cancer, such as the presence or absence of the estrogen receptor ESR1, and BRCA1 and sporadic tumors, and to provide information on the likelihood of tumor distant metastases within five years of initial diagnosis. The invention relates to methods of using these markers to distinguish these conditions. The invention also provides methods of classifying and treating patients based on prognosis. The invention also relates to kits containing ready-to-use microarrays and computer software for data analysis using the diagnostic, prognostic and statistical methods disclosed herein.
摘要翻译：本发明涉及其表达与乳腺癌相关的遗传标记。具体地，本发明提供了一组标志物，其表达模式可用于区分与乳腺癌相关的临床病症，例如雌激素受体ESR1和BRCA1和散发性肿瘤的存在或不存在，并提供关于肿瘤可能性的信息初步诊断五年内远处转移。本发明涉及使用这些标记来区分这些条件的方法。本发明还提供了基于预后对患者进行分类和治疗的方法。本发明还涉及包含即用型微阵列的试剂盒和用于使用本文公开的诊断，预后和统计学方法进行数据分析的计算机软件。

9. 发明申请

US20120072124A1 GENES ASSOCIATED WITH PROGRESSION AND RESPONSE IN CHRONIC MYELOID LEUKEMIA AND USES THEREOF 审中-公开
标题翻译：与慢性粒细胞白血病有关的进展与反应的基因及其用途
公开(公告)号：US20120072124A1
公开(公告)日：2012-03-22
申请号：US13207282
申请日：2011-08-10
申请人： Jerald P. Radich , Hongyue Dai , Mao Mao , Janell M. Schelter , Peter S. Linsley
发明人： Jerald P. Radich , Hongyue Dai , Mao Mao , Janell M. Schelter , Peter S. Linsley
IPC分类号： G06F19/20 , G01N33/50
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/112 , C12Q2600/136 , C12Q2600/158 , Y02A90/26
摘要： The invention provides molecular markers that are associated with the progression of chronic myeloid leukemia (CML), and methods and computer systems for monitoring the progression of CML in a patient based on measurements of these molecular markers. The present invention also provides CML target genes, and methods and compositions for treating CML patients by modulating the expression or activity of these CML target genes and/or their encoded proteins. The invention also provides genes that are associated with resistance to imatinib mesylate (Gleevec™) treatment in CML patients, and methods and compositions for determining the responsiveness of a CML patient to imatinib mesylate treatment based on measurements of these genes and/or their encoded proteins. The invention also provides methods and compositions for enhancing the effect of Gleevec™ by modulating the expression or activity of these genes and/or their encoded proteins.
摘要翻译：本发明提供了与慢性骨髓性白血病（CML）进展相关的分子标记，以及用于基于这些分子标记物的测量来监测患者中CML进展的方法和计算机系统。本发明还提供CML靶基因，以及通过调节这些CML靶基因和/或其编码蛋白的表达或活性来治疗CML患者的方法和组合物。本发明还提供了与CML患者中对伊马替尼甲磺酸盐（Gleevec TM）治疗有关的基因，以及基于这些基因和/或其编码蛋白质的测量来确定CML患者对甲磺酸伊马替尼治疗的反应性的方法和组合物。本发明还提供了通过调节这些基因和/或其编码的蛋白质的表达或活性来增强Gleevec TM的作用的方法和组合物。

10. 发明授权

US08014957B2 Genes associated with progression and response in chronic myeloid leukemia and uses thereof 失效
标题翻译：与慢性骨髓性白血病中进展和反应相关的基因及其用途
公开(公告)号：US08014957B2
公开(公告)日：2011-09-06
申请号：US11640517
申请日：2006-12-14
申请人： Jerald P. Radich , Hongyue Dai , Mao Mao , Janell M. Schelter , Peter S. Linsley
发明人： Jerald P. Radich , Hongyue Dai , Mao Mao , Janell M. Schelter , Peter S. Linsley
IPC分类号： G01N33/48
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/112 , C12Q2600/136 , C12Q2600/158 , Y02A90/26
摘要： The invention provides molecular markers that are associated with the progression of chronic myeloid leukemia (CML), and methods and computer systems for monitoring the progression of CML in a patient based on measurements of these molecular markers. The present invention also provides CML target genes, and methods and compositions for treating CML patients by modulating the expression or activity of these CML target genes and/or their encoded proteins. The invention also provides genes that are associated with resistance to imatinib mesylate (Gleevec™) treatment in CML patients, and methods and compositions for determining the responsiveness of a CML patient to imatinib mesylate treatment based on measurements of these genes and/or their encoded proteins. The invention also provides methods and compositions for enhancing the effect of Gleevec™ by modulating the expression or activity of these genes and/or their encoded proteins.
摘要翻译：本发明提供了与慢性骨髓性白血病（CML）进展相关的分子标记，以及用于基于这些分子标记物的测量来监测患者中CML进展的方法和计算机系统。本发明还提供CML靶基因，以及通过调节这些CML靶基因和/或其编码蛋白的表达或活性来治疗CML患者的方法和组合物。本发明还提供了与CML患者中对伊马替尼甲磺酸盐（Gleevec TM）治疗有关的基因，以及基于这些基因和/或其编码蛋白质的测量来确定CML患者对甲磺酸伊马替尼治疗的反应性的方法和组合物。本发明还提供了通过调节这些基因和/或其编码的蛋白质的表达或活性来增强Gleevec TM的作用的方法和组合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式